Prognostic value of the peripheral blood lymphocyte/monocyte ratio combined with 18F-FDG PET/CT in patients with diffuse large B-cell lymphoma

IF 2.5 4区 医学 Q3 ONCOLOGY
Wenke Wu , Lidong Zhao , Ying Wang , Peng Chen , Xiaoshuai Yuan , Lei Miao , Yuanxin Zhu , Jianping Mao , Zhimei Cai , Yajun Ji , Lei Wang , Tao Jia
{"title":"Prognostic value of the peripheral blood lymphocyte/monocyte ratio combined with 18F-FDG PET/CT in patients with diffuse large B-cell lymphoma","authors":"Wenke Wu ,&nbsp;Lidong Zhao ,&nbsp;Ying Wang ,&nbsp;Peng Chen ,&nbsp;Xiaoshuai Yuan ,&nbsp;Lei Miao ,&nbsp;Yuanxin Zhu ,&nbsp;Jianping Mao ,&nbsp;Zhimei Cai ,&nbsp;Yajun Ji ,&nbsp;Lei Wang ,&nbsp;Tao Jia","doi":"10.1016/j.currproblcancer.2024.101066","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>To explore the prognostic value of the peripheral blood lymphocyte/monocyte ratio (LMR) combined with <sup>18</sup>F-FDG PET/CT for diffuse large B-cell lymphoma (DLBCL).</p></div><div><h3>Methods</h3><p>The clinical data of 203 patients with primary DLBCL who were hospitalized to the First People's Hospital of Lianyungang between January 2017 and December 2022 were retrospectively analyzed. Before and after three courses of treatment, PET/CT was performed on forty DLBCL patients. The subject operating characteristic (ROC) curve has been employed to determine the most effective LMR cutoff points. According to the criteria for assessing the efficacy of Lugano lymphoma, the PET/CT findings after 3 courses of treatment were specified as complete remission (CR), partial remission (PR), stable disease (SD) and disease progression (PD). The CR group, PR+SD group, and PD group were the three groups created from the four outcomes. Results were analyzed using the Cox proportional risk model, the Kaplan-Meier method (K-M), and the log-rank test.</p></div><div><h3>Results</h3><p>An optimal cutoff point of 3.00 for the LMR in 203 patients was determined by the SPSS 26 software ROC curve. When LMR≥3.00, the 1-year, 3-year, and 5-year OS (Overall Survival) rates are 98%, 88%, and 64% respectively, and the PFS (Progression-free Survival) rates are 90%, 75%, and 56% respectively. When LMR &lt;3.00, the 1-year, 3-year, and 5-year OS rates are 96%, 72%, and 28% respectively, and the PFS rates are 83%, 60%, and 28% respectively. A lower LMR was substantially related with shorter OS, and PFS, according to a K-M survival analysis (<em>P</em>&lt;0.005). LMR&lt;3.00 was an independent predictor of OS, based on a multifactorial Cox analysis (<em>P</em>=0.037). K-M survival analysis of the <sup>18</sup>F-FDG PET/CT results of 40 patients revealed that both OS and PFS were statistically significant (<em>P</em>&lt;0.001). Patients were separated into 3 groups combining LMR and <sup>18</sup>F-FDG PET/CT: PET/CT CR patients with LMR≥3.00, PET/CT PD patients with LMR&lt;3.00, and others. The Kaplan-Meier analysis revealed that there were significant differences in OS and PFS for each of the three groups (<em>P</em>&lt;0.001). ROC curves showed that the area under the curve (AUC) of the combined testing of the two was 0.735, and the combined testing of the two was better compared to testing alone (PET/CT AUC=0.535, LMR AUC=0.567). This indicates that combining both PET/CT and LMR is a favorable prediction for DLBCL.</p></div><div><h3>Conclusion</h3><p>A decreased LMR at initial diagnosis suggests an unfavorable prognosis for DLBCL patients; For patients with DLBCL, combining <sup>18</sup>F-FDG PET/CT and the LMR has a better predictive value.</p></div>","PeriodicalId":55193,"journal":{"name":"Current Problems in Cancer","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Problems in Cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0147027224000072","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective

To explore the prognostic value of the peripheral blood lymphocyte/monocyte ratio (LMR) combined with 18F-FDG PET/CT for diffuse large B-cell lymphoma (DLBCL).

Methods

The clinical data of 203 patients with primary DLBCL who were hospitalized to the First People's Hospital of Lianyungang between January 2017 and December 2022 were retrospectively analyzed. Before and after three courses of treatment, PET/CT was performed on forty DLBCL patients. The subject operating characteristic (ROC) curve has been employed to determine the most effective LMR cutoff points. According to the criteria for assessing the efficacy of Lugano lymphoma, the PET/CT findings after 3 courses of treatment were specified as complete remission (CR), partial remission (PR), stable disease (SD) and disease progression (PD). The CR group, PR+SD group, and PD group were the three groups created from the four outcomes. Results were analyzed using the Cox proportional risk model, the Kaplan-Meier method (K-M), and the log-rank test.

Results

An optimal cutoff point of 3.00 for the LMR in 203 patients was determined by the SPSS 26 software ROC curve. When LMR≥3.00, the 1-year, 3-year, and 5-year OS (Overall Survival) rates are 98%, 88%, and 64% respectively, and the PFS (Progression-free Survival) rates are 90%, 75%, and 56% respectively. When LMR <3.00, the 1-year, 3-year, and 5-year OS rates are 96%, 72%, and 28% respectively, and the PFS rates are 83%, 60%, and 28% respectively. A lower LMR was substantially related with shorter OS, and PFS, according to a K-M survival analysis (P<0.005). LMR<3.00 was an independent predictor of OS, based on a multifactorial Cox analysis (P=0.037). K-M survival analysis of the 18F-FDG PET/CT results of 40 patients revealed that both OS and PFS were statistically significant (P<0.001). Patients were separated into 3 groups combining LMR and 18F-FDG PET/CT: PET/CT CR patients with LMR≥3.00, PET/CT PD patients with LMR<3.00, and others. The Kaplan-Meier analysis revealed that there were significant differences in OS and PFS for each of the three groups (P<0.001). ROC curves showed that the area under the curve (AUC) of the combined testing of the two was 0.735, and the combined testing of the two was better compared to testing alone (PET/CT AUC=0.535, LMR AUC=0.567). This indicates that combining both PET/CT and LMR is a favorable prediction for DLBCL.

Conclusion

A decreased LMR at initial diagnosis suggests an unfavorable prognosis for DLBCL patients; For patients with DLBCL, combining 18F-FDG PET/CT and the LMR has a better predictive value.

外周血淋巴细胞/单核细胞比值结合 18F-FDG PET/CT 对弥漫大 B 细胞淋巴瘤患者的预后价值
目的 探讨外周血淋巴细胞/单核细胞比值(LMR)联合18F-FDG PET/CT对弥漫大B细胞淋巴瘤(DLBCL)的预后价值。方法 回顾性分析2017年1月至2022年12月期间在连云港市第一人民医院住院治疗的203例原发性DLBCL患者的临床资料。在三个疗程治疗前后,对40名DLBCL患者进行了PET/CT检查。采用受试者操作特征曲线(ROC)来确定最有效的LMR截断点。根据卢加诺淋巴瘤疗效评估标准,三个疗程治疗后的 PET/CT 结果分为完全缓解(CR)、部分缓解(PR)、疾病稳定(SD)和疾病进展(PD)。CR组、PR+SD组和PD组是从这四种结果中产生的三个组。采用 Cox 比例风险模型、Kaplan-Meier 法(K-M)和对数秩检验对结果进行分析。结果通过 SPSS 26 软件 ROC 曲线确定了 203 例患者 LMR 的最佳临界点为 3.00。当 LMR≥3.00 时,1 年、3 年和 5 年 OS(总生存率)分别为 98%、88% 和 64%,PFS(无进展生存率)分别为 90%、75% 和 56%。当 LMR 为 3.00 时,1 年、3 年和 5 年的 OS 率分别为 96%、72% 和 28%,PFS 率分别为 83%、60% 和 28%。根据 K-M 生存分析,较低的 LMR 与较短的 OS 和 PFS 有很大关系(P<0.005)。根据多因素 Cox 分析,LMR<3.00 是 OS 的独立预测因子(P=0.037)。对 40 例患者的 18F-FDG PET/CT 结果进行的 K-M 生存分析表明,OS 和 PFS 均有统计学意义(P<0.001)。结合 LMR 和 18F-FDG PET/CT 将患者分为 3 组:LMR≥3.00 的 PET/CT CR 患者、LMR<3.00 的 PET/CT PD 患者和其他患者。Kaplan-Meier 分析显示,三组患者的 OS 和 PFS 均有显著差异(P<0.001)。ROC曲线显示,两者联合检测的曲线下面积(AUC)为0.735,与单独检测相比,两者联合检测的效果更好(PET/CT AUC=0.535,LMR AUC=0.567)。结论 初诊时 LMR 降低提示 DLBCL 患者预后不良;对于 DLBCL 患者,联合使用 18F-FDG PET/CT 和 LMR 有更好的预测价值。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Current Problems in Cancer
Current Problems in Cancer 医学-肿瘤学
CiteScore
5.10
自引率
0.00%
发文量
71
审稿时长
15 days
期刊介绍: Current Problems in Cancer seeks to promote and disseminate innovative, transformative, and impactful data on patient-oriented cancer research and clinical care. Specifically, the journal''s scope is focused on reporting the results of well-designed cancer studies that influence/alter practice or identify new directions in clinical cancer research. These studies can include novel therapeutic approaches, new strategies for early diagnosis, cancer clinical trials, and supportive care, among others. Papers that focus solely on laboratory-based or basic science research are discouraged. The journal''s format also allows, on occasion, for a multi-faceted overview of a single topic via a curated selection of review articles, while also offering articles that present dynamic material that influences the oncology field.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信